CymaBay Therapeutics
- Biotech or pharma, therapeutic R&D
Cymab is a preclinical-stage company with a mission to transform the treatment of patients with cold tumors.
Using its novel and patented TIMS platform, Cymab is developing bispecific antibodies that deliver the body’s own IFNγ directly into cold tumors while simultaneously blocking PD-1—turning immune-desert tumors into inflamed, treatable lesions. This dual mechanism promotes immune cell infiltration, remodels fibrotic stroma, and drives potent tumor regression, all with a favorable safety profile.
Our lead drug candidate, CYM-PD1, is being developed for advanced hepatocellular carcinoma (HCC)—a deadly cancer with limited treatment options for patients who progress after first-line therapy.
We are raising a seed round of 10 mUSD in H2 2025. We welcome early investor interest in this first-in-class approach.
If you are interested, we are present at BIO and can be contacted via the platform or by email at johan@cymab.bio.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}